• 图文组件

  • 科室介绍

  • 图文组件
  • 图文组件
就医指南

  科室概况

首页 English version

Overview
Department of Rheumatology and Immunology, Peking University People's Hospital, the Center of Clinical Immunology, Peking University, is one of the earliest and largest rheumatology centers in China. As a top National Key Center specialized in Rheumatology, the center has been titled as a National Center of Excellence in Rheumatology (certified in 2013), a National Key Laboratory in Clinical Immunology of the Ministry of Education of China (certified in 2005), Innovation team of the Ministry of Education of China (certified in 2011), Beijing Key Laboratory (certified in 2012), and the only International Cooperation Base in Rheumatic Diseases in Beijing (certified in 2015) and Asia Pacific League of Associations for Rheumatology (APLAR) Center of Excellence  (certified in 2016) .

 

The center currently consists of 4 campuses: Beijing, Tongzhou and Qingdao and Shijiazhuang, respectively. The center comprised of 110 hospital beds, and 118 staffs/researchers, including 19 Professors/chief physicians, 18 Associate professors/associate chief physicians, 11 attending physicians, 11 residents, 49 nurses and 9 technicians. There are 27 PIs, with around 50 SCI papers each year published in peer-reviewed journals including Lancet Rheum, JAMA Netw open, ARD and Nat  Commun etc.

 

The academic participations of the staff include Past-President of International Leagues Associations of Rheumatology (ILAR), Past-President of Asia Pacific League of Associations for Rheumatology (APLAR), Past-President of Chinese Rheumatology Association, President of Clinical Immunology Association of China, President of Chinese association of women in Rheumatology and Immunology, member of WHO-ICC, member of Chinese Rheumatology Association, member of Chinese Rheumatology Association, etc. The staff also serve as Associate Editor of Clinical Rheumatology, Int J Rheumatic Diseases, Semin Arthritis Rheu, Journal of Gene Medicine and Immunology, Chief Editor of Chinese Journal of Rheumatology, Journal of Clinical Immunology and Rheumatology, editorial board member of Nature Reviews Rheumatology, Lancet Rheumatology, Rheumatology, Current Opinion in Rheumatology, Ann Rheum Dis, Clin Exp Rheumatology, Chinese Journal of Internal Medicine and National Medical Journal of China, reviewers of Lupus, J Rheumatology and over 10 other domestic and international journals.

 

A number of academic honors have been achieved, including "973" Chief Scientist, CMB Distinguished Professor, Winners of National Outstanding Youth Fund, Yang Wu Prize winner, the Ministry of Education Cross-Century Talents, China Medical Science and Technology Prize, China Medical Science and Technology Award, University Scientific Research and Technological Progress Award, Beijing Science Nova, National Tech-Distinguished Talent, National Ten Thousand Talents Plan, Young Changjiang Scholar etc.

The center has published over 850 papers as first or corresponding authors in Nature Medicine, Lancet Rheumatology, Immunity, Science and JAMA Network Open, Cell Host Microbe, Immunity, Annals of Internal Medicine, Annals of the Rheumatic Diseases, Arthritis Rheum, Autoimmunity, etc, among which over 400 are SCI papers. The center edited, translated or participated in the editing of over 30 books in rheumatology including Rheumatology, Kelley's Textbook of Rheumatology, Sjögren’s syndrome, etc.

 

The center focuses on rheumatic diseases such as rheumatoid arthritis, systemic lupus erythematosus and Sjögren’s syndrome, and has researched and developed more than 20 new specific markers and immune techniques in diagnosis, such as antibodies to the citrullinated HPVP, antibodies to citrullinated fibrinogen peptide, anti-mDNA, anti-nucleosome, anti- M3 receptor, anti-α-fodrin antibodies and SR-A. Meanwhile, over 10 novel immune-based therapies have been used such as ld-IL-2 for SLE/RA/DM, T cell vaccination for SLE and RA.

 

Publications

  1. He J, Zhang X, Wei YB, Sun XL, Chen YP, Deng J, Jin YB, Gan YZ, Hu X, Jia RL, Xu CH, Hou ZH, Leong YA, Zhu L, Feng JH, An Y, Jia Y, Li C, Liu X, Ye H, Ren LM, Li R, Yao HH, Li YH, Chen S, Zhang XW, Su Y, Guo JP, Shen N, Morand EF, Yu D, Li ZG. Low-dose interleukin-2 treatment selectively modulates CD4(+) T cell subsets in patients with systemic lupus erythematosus. NAT MED 2016;22:991.
  2. Chen XJ, Sun XL, Yang W, Yang B, Zhao XZ, Chen ST, He LL, Chen H, Yang CM, Xiao L, Chang Z, Guo JP, He J, Zhang FP, Zheng F, Hu ZB, Yang ZY, Lou JZ, Zheng WJ, Qi H, Xu CQ, Zhang H, Shan HY, Zhou XJ, Wang QW, Shi Y, Lai LH, Li ZG, Liu WL. An autoimmune disease variant of IgG1 modulates B cell activation and differentiation. SCIENCE 2018;362:700.
  3. Liu Y, Mu R, Gao YP, Dong J, Zhu L, Ma YY, Li YH, Zhang HQ, Han D, Zhang Y, McInnes IB, Zhang JG, Shen BF, Yang G, Li ZG. A Cytomegalovirus Peptide-Specific Antibody Alters Natural Killer Cell Homeostasis and Is Shared in Several Autoimmune Diseases. Cell Host& Microbe 2016;19:400.
  4. Fanlei Hu; Xiang Jiang; Chunqing Guo; Yingni Li; Shixian Chen; Wei Zhang; Yan Du; Ping Wang; Xu Liu; Limin Ren; Xiaoying Zhang; Jianping Guo; Hudan Pan; Yin Su; Huanfa Yi; Hua Ye; Daming Zuo; Juan Li; Yongfu Wang; Ru Li; Liang Liu; Zhanguo Li .Scavenger receptor-A is a biomarker and effector of rheumatoid arthritis: A large-scalemulticenter study. Nature Communications. 2020, 11(1): 1-14.
  5. He J, Chu Y, Li J, Meng Q, Liu Y, Jin J, Wang Y, Wang J, Huang B, Shi L, Shi X, Tian J, Zhufeng Y, Feng R, Xiao W, Gan Y, Guo J, Shao C, Su Y, Hu F, Sun X, Yu J, Kang Y, Li Z. Intestinal butyrate-metabolizing species contribute to autoantibody production and bone erosion in rheumatoid arthritis. Science Advances. 2022 Feb 11;8(6):eabm1511.
  6. Yinhua Zhu, Lu Wang, Jing Li, Yuan Zhao, Xuerong Yu, Ping Liu, Xiaobing Deng, Jingjing Liu, Fan Yang, Yini Zhang, Jiaojiao Yu, Luhua Lai, Chu Wang, Zhanguo Li, Lei Wang, Tuoping Luo. Photoaffinity labeling coupled with proteomics identify PDI-ADAM17 module is targeted by (-)-vinigrol to induce TNFR1 shedding and ameliorate rheumatoid arthritis in mice. Cell Chem Biol. 2023 Oct 23:S2451-9456(23)00339-2.
  7. Li C, Huang J, Wu H, Li F, Zhao Y, Zhang Z, Li S, Wei H, Zhang M, Sun H, Yang J, Li Q, Li X, Qi W, Wei W, Li Y, Li Z, Wang Y, Zhang F, Wu H, Shuai Z, Wu Z, Li Y, Jia S, Jia Y, Xiao F, Mu R, Li Z. Management of Rheumatoid Arthritis With a Digital Health Application: A Multicenter, Pragmatic Randomized Clinical Trial. JAMA Network Open. 2023 Apr 3;6(4):e238343.
  8. He J, Chen J, Miao M, Zhang R, Cheng G, Wang Y, Feng R, Huang B, Luan H, Jia Y, Jin Y, Zhang X, Shao M, Wang Y, Zhang X, Li J, Zhao X, Wang H, Liu T, Xiao X, Zhang X, Su Y, Mu R, Ye H, Li R, Liu X, Liu Y, Li C, Liu H, Hu F, Guo J, Liu W, Zhang WB, Jacob A, Ambrus JL Jr, Ding C, Yu D, Sun X, Li Z. Efficacy and Safety of Low-Dose Interleukin 2 for Primary Sjögren Syndrome: A Randomized Clinical Trial. JAMA Network Open. 2022 Nov 1;5(11):e2241451.
  9. Sun X, Li R, Cai Y, Al-Herz A, Lahiri M, Choudhury MR, Hidayat R, Suryana BPP, Kaneko Y, Fujio K, Van Hung N, Pandya S, Pang LK, Katchamart W, Sigdel KR, Paudyal B, Narongroeknawin P, Chevaisrakul P, Sun F, Lu Y, Ho C, Yeap SS, Li Z; APLAR RA SIG group. Clinical remission of rheumatoid arthritis in a multicenter real-world study in Asia-Pacific region. The Lancet Regional Health - Western Pacific. 2021 Aug 12;15:100240.
  10. Mu R, Li C, Li X, Ke Y, Zhao L, Chen L, Wu R, Wu Z, Zuo X, Xie Y, Chen J, Wei W, Liu Y, Li Z, Dai L, Sun L, Liu X, Li Z. Effectiveness and safety of iguratimod treatment in patients with active rheumatoid arthritis in Chinese: A nationwide, prospective real-world study. The Lancet Regional Health - Western Pacific. 2021 Mar 22;10:100128.
  11. Yue Yang, Jingyang Li,Ju Liu,Lin Liu, Yongfu Wang, Jiankang Hu,Zhijun Li, Jieruo Gu,Xiao Zhang, Zhengyu Xiao, Junjie Zheng,Lin Liu, Zhanguo Li,and James Cheng-Chung Wei. Safety and efficacy of peficitinib in Asian patients with rheumatoid arthritis who had an inadequate response or intolerance to methotrexate: results of a multicenter, randomized, double-blind, placebo-controlled phase 3 study. The Lancet Regional Health - Western Pacific 2023; 100925.
  12. He, J., X.L. Sun, and Z.G. Li, Low-dose IL-2 for patients with systemic lupus erythematosus. LANCET RHEUMATOLOGY, 2019. 1(4): p. E203-E203
  13. Haotian Zhou #, Xiaozhen Zhao #, Ruijun Zhang, Miao Miao, Wenwen Pei, Zijun Li, Yimin Li, Jing He, Zhanguo Li, Xiaolin Sun. Low-dose IL-2 mitigates glucocorticoid-induced Treg impairment and promotes improvement of SLE. Signal Transduct Target Ther 2023 Apr 3;8(1):141.
  14. Zhang X, Miao M, Zhang R, Liu X, Zhao X, Shao M, Liu T, Jin Y, Chen J, Liu H, Zhang X, Li Y, Zhou Y, Yang Y, Li R, Yao H, Liu Y, Li C, Li Y, Ren L, Su Y, Sun X, He J, Li Z. Efficacy and safety of low-dose interleukin-2 in combination with methotrexate in patients with active rheumatoid arthritis: a randomized, double-blind, placebo-controlled phase 2 trial. Signal Transduct Target Ther. 2022 Mar 7;7(1):67.
  15. Li J, Jin J, Li S, Zhong Y, Jin Y, Zhang X, Xia B, Zhu Y, Guo R, Sun X, Guo J, Hu F, Xiao W, Huang F, Ye H, Li R, Zhou Y, Xiang X, Yao H, Yan Q, Su L, Wu L, Luo T, Liu Y, Guo X, Qin J, Qi H, He J, Wang J, Li Z. Tonsillar Microbiome-Derived Lantibiotics Induce Structural Changes of IL-6 and IL-21 Receptors and Modulate Host Immunity. ADVANCED SCIENCE (WEINH). 2022 Oct;9(30):e2202706.
  16. Xia M, Liu J, Liu S, Chen K, Lin H, Jiang M, Xu X, Xue Y, Liu W, Gu Y, Zhang X, Li Z, Yi L, Qian Y, Zhou C, Li R, Zhang X, Li Z, Cao X. Ash1l and lnc-Smad3 coordinate Smad3 locus accessibility to modulate iTreg polarization and T cell autoimmunity. NATURE COMMUNICATIONS. 2017 Jun 9;8:15818.
  17. Wang T, Sun XL, Zhao J, Zhang J, Zhu HQ, Li C, Gao N, Jia Y, Xu DK, Huang FP, Li NL, Lu LW, Li ZG. Regulatory T cells in rheumatoid arthritis showed increased plasticity toward Th17 but retained suppressive function in peripheral blood. ANN RHEUM DIS 2015;74:1293.
  18. Li ZG. A new look at rheumatology in China-opportunities and challenges. NAT REV RHEUMATOL 2015;11:313.
  19. Guo CQ, Hu FL, Yi HF, Feng ZT, Li CZ, Shi LJ, Li YN, Liu HJ, Yu XF, Wang HX, Li J, Li ZG, Wang XY. Myeloid-derived suppressor cells have a proinflammatory role in the pathogenesis of autoimmune arthritis. ANN RHEUM DIS 2016;75:278.
  20. Du Y, Su Y, He J, Yang Y, Shi YM, Cui Y, Luo CN, Wu XY, Liu X, Hu FL, Ma XX, Zheng L, Zhang J, Zuo XB, Sheng YJ, Wu LJ, Zhang XJ, Guo JP, Li ZG. Impact of the leucocyte immunoglobulin-like receptor A3 (LILRA3) on susceptibility and subphenotypes of systemic lupus erythematosus and Sjogren's syndrome. ANN RHEUM DIS 2015;74:2070.
  21. Hu FL, Mu R, Zhu JX, Shao WW, Shi LJ, Cohen PL, Qiu XY, Li ZG. Hypoxia-Inducible Factor-1 alpha: Trigger of Toll-Like Receptor Signalling-Engaged Inflammation in Rheumatoid Arthritis. ANN RHEUM DIS 2014;73:928-936.
  22. Zhou P, Chen J, He J, Zheng T, Yunis J, Makota V, Alexandre YO, Gong F, Zhang X, Xie W, Li Y, Shao M, Zhu Y, Sinclair JE, Miao M, Chen Y, Short KR, Mueller SN, Sun X, Yu D, Li Z. Low-dose IL-2 therapy invigorates CD8+ T cells for viral control in systemic lupus erythematosus. PLoS Pathog. 2021 Oct 7;17(10):e1009858.
  23. Yu D, Walker LSK, Liu Z, Linterman MA, Li Z. Targeting TFH cells in human diseases and vaccination: rationale and practice. Nat Immunol. 2022 Aug;23(8):1157-1168.
  24. Li, ZG; He, J; Yu, D. The rise of IL-2 therapy a picture beyond T-reg cells. NATURE REVIEWS RHEUMATOLOGY. 2017; 13(6): 386.
  25. He J, Zhang R, Shao M, Zhao X, Miao M, Chen J, Liu J, Zhang X, Zhang X, Jin Y, Wang Y, Zhang S, Zhu L, Jacob A, Jia R, You X, Li X, Li C, Zhou Y, Yang Y, Ye H, Liu Y, Su Y, Shen N, Alexander J, Guo J, Ambrus J, Lin X, Yu D, Sun X, Li Z. Efficacy and safety of low-dose IL-2 in the treatment of systemic lupus erythematosus: a randomised, double-blind, placebo-controlled trial. ANN RHEUM DIS. 2020 Jan;79(1):141-149.
  26. Guo J, Zhang T, Cao H, Li X, Liang H, Liu M, Zou Y, Zhang Y, Wang Y, Sun X, Hu F, Du Y, Mo X, Liu X, Yang Y, Yang H, Wu X, Zhang X, Jia H, Jiang H, Hou Y, Liu X, Su Y, Zhang M, Yang H, Wang J, Sun L, Liu L, Padyukov L, Lai L, Yamamoto K, Zhang X, Klareskog L, Xu X, Li Z. Sequencing of the MHC region defines HLA-DQA1 as the major genetic risk for seropositive rheumatoid arthritis in Han Chinese population. ANN RHEUM DIS.2019 Jun;78(6):773-780.
  27. Bonfá E, Gossec L, Isenberg DA, Li Z, Raychaudhuri S. How COVID-19 is changing rheumatology clinical practice. NAT REV RHEUMATOL. 2021 Jan;17(1):11-15.
  28. Smolen JS, Landewé RBM, Bergstra SA, Kerschbaumer A, Sepriano A, Aletaha D, Caporali R, Edwards CJ, Hyrich KL, Pope JE, de Souza S, Stamm TA, Takeuchi T, Verschueren P, Winthrop KL, Balsa A, Bathon JM, Buch MH, Burmester GR, Buttgereit F, Cardiel MH, Chatzidionysiou K, Codreanu C, Cutolo M, den Broeder AA, El Aoufy K, Finckh A, Fonseca JE, Gottenberg JE, Haavardsholm EA, Iagnocco A, Lauper K, Li Z, McInnes IB, Mysler EF, Nash P, Poor G, Ristic GG, Rivellese F, Rubbert-Roth A, Schulze-Koops H, Stoilov N, Strangfeld A, van der Helm-van Mil A, van Duuren E, Vliet Vlieland TPM, Westhovens R, van der Heijde D. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. ANN RHEUM DIS. 2023 Jan;82(1):3-18.
  29. Wang, T; Sun, XL; Zhao, J; Zhang, J; Zhu, HQ; Li, C; Gao, N; Jia, Y; Xu, DK; Huang, FP; Li, NL; Lu, LW; Li, ZG. Regulatory T cells in rheumatoid arthritis showed increased plasticity toward Th17 but retained suppressive function in peripheral blood. ANN RHEUM DIS. 2015; 74(6): 1293-1301.
  30. Hu W, Zhang Y, Sun X, Zhang T, Xu L, Xie H, Li Z, Liu W, Lou J, Chen W. FcγRIIB-I232T polymorphic change allosterically suppresses ligand binding. Elife. 2019 Jul 25;8:e46689.
  31. Wen, LL; Zhu, CH; Zhu, ZW; Yang, C; Zheng, XD; Liu, L; Zuo, XB; Sheng, YJ; Tang, HY; Liang, B; Zhou, Y; Li, P; Zhu, J; Ding, YT; Chen, G; Gao, JP; Tang, LL; Cheng, YY; Sun, JY; Elango, T; Kafle, A; Yu, RX; Xue, K; Zhang, YH; Li, F; Li, ZG; Guo, JP; Zhang, X; Zhou, C; Tang, YJ; Shen, N; Wang, M; Yu, XQ; Liu, SX; Fan, X; Gao, M; Xiao, FL; Wang, PG; Wang, ZX; Zhang, AP; Zhou, FS; Sun, LD; Yang, S; Xu, JH; Yin, XY; Cui, Y; Zhang, XJ. Exome-wide association study identifies four novel loci for systemic lupus erythematosus in Han Chinese population. ANN RHEUM DIS. 2018; 77(3):417-422.
  32. Takeuchi, T; Genovese, MC; Haraoui, B; Li, ZG; Xie, L; Klar, R; Pinto-Correia, A; Otawa, S; Lopez-Romero, P; de la Torre, I; Macias, W; Rooney, TP; Smolen, JS.Dose reduction of baricitinib in patients with rheumatoid arthritis achieving sustained disease control: results of a prospective study. ANN RHEUM DIS. 2019; 78(2):171-178.
  33. Xu, LL; Xia, MD; Guo, J; Sun, XL; Li, H; Xu, CG; Gu, XM; Zhang, HW; Yi, JY; Fang, Y; Xie, HY; Wang, J; Shen, ZX; Xue, BX; Sun, YJ; Meckel, T; Chen, YH; Hu, ZB; Li, ZG; Xu, CQ; Gong, HP; Liu, WL. Impairment on the lateral mobility induced by structural changes underlies the functional deficiency of the lupus-associated polymorphism Fc gamma RIIB-T232. JOURNAL OF EXPERIMENTAL MEDICINE. 2016; 213(12): 2707-2727.
  34. Zhang Y, Li Y, Zhang J, Chen X, Zhang R, Sun G, Jiang B, Fan K, Li Z, Yan X. Nanocage-Based Capture-Detection System for the Clinical Diagnosis of Autoimmune Disease. SMALL. 2021 Jun;17(25):e2101655.
  35. Hu S, Liu X, Li T, Li Z, Hu F. LAG3 (CD223) and autoimmunity: Emerging evidence. J Autoimmun. 2020 Aug;112:102504.

……850 papers.

 

 

 

Contact Us
Department of Rheumatology and Immunology, Peking University People’s Hospital,
11# Xizhimen South Street, Xicheng District, Beijing, China 100044

Email: rheumatology1984@163.com

Fax: +86-10-88378021
Telephone: +86-10-88324173

地址：北京市西城区西直门南大街11号北京大学人民医院风湿免疫科/风湿免疫研究所

医院电话：010-88326666 ( 14:00--23:00 点) 010-88325230 ( 08:00--17:00 点)

Email ：rheumatology1984@163.com 京ICP备09002104号

公安局网站备案信息更新序号：12986

技术支持：河马建站    

版权所有 © 北京大学人民医院风湿免疫研究所 技术支持：优河马